A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.

被引：1
|
作者：
Shitara, Kohei
Bang, Yung-Jue
Chung, Hyun Cheol
Yabusaki, Hiroshi
Iwasa, Satoru
Sakai, Daisuke
Muro, Kei
Sugimoto, Naotoshi
Yasui, Hisateru
Gamoh, Makio
Murakawa, Yasuko
Negoro, Yuji
Nishina, Tomohiro
Hosaka, Hisashi
Omuro, Yasushi
Kawaguchi, Yoshinori
Sugihara, Masahiro
Saito, Kaku
Dalal, Rita
Yamaguchi, Kensei
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Niigata Canc Ctr Hosp, Niigata, Japan
[5] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[6] Osaka Univ Hosp, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[10] Osaki Citizen Hosp, Osaki, Japan
[11] Miyagi Canc Ctr, Natori, Miyagi, Japan
[12] Kochi Hlth Sci Ctr, Kochi, Japan
[13] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[14] Gunma Prefectural Canc Ctr, Ota, Japan
[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[18] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [2] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer
    Yamashita, Toshinari
    Shimomura, Akihiko
    Takano, Toshimi
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Kikumori, Kunika
    Kamiyama, Emi
    Kamio, Takahiro
    Nakamura, Ryo
    Shinkai, Tetsu
    Takahashi, Shunji
    CANCER RESEARCH, 2020, 80 (04)
  • [4] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [5] A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer.
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb C.
    Wang, Kongming
    Saxena, Kapil
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [7] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer
    Hurvitz, S. A.
    Galsky, M. D.
    Shahidi, J.
    Zhang, G.
    Raza, S.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
    Yoshino, T.
    Siena, S.
    Di Bartolomeo, M.
    Raghav, K.
    Masuishi, T.
    Loupakis, F.
    Kawakami, H.
    Yamaguchi, K.
    Nishina, T.
    Fakih, M.
    Elez, E.
    Rodriguez, J.
    Ciardiello, F.
    Saxena, K.
    Yamamoto, E.
    Kobayashi, K.
    Bako, E.
    Okuda, Y.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
  • [10] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345